Existing oncology therapeutics are either so specific they can target only part of a tumor, or so generalized they kill healthy tissue.

Immune checkpoint inhibitors (ICIs) emerged in the US about 15 years ago as an exciting class of cancer treatments that have ...

Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on ...

Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...

Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, ...

Researchers in Dr. Louis Weiner’s lab at the Georgetown University Lombardi Comprehensive Cancer Center are examining ...

Posters will review product characterization and manufacturing data on T-knife’s lead program, TK-6302, a supercharged PRAME ...

Scientists have developed a way to engineer immune cells that specifically target tumors. The application of engineering ...

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress ...

In recognition of Pancreatic Cancer Awareness Month, join us to explore how cutting-edge technologies are transforming our ...